🎧 New: AI-Generated Podcasts Turn your study notes into engaging audio conversations. Learn more

Alzheimer's Disease Causative Pathway and Current Clinical Trials
17 Questions
0 Views

Alzheimer's Disease Causative Pathway and Current Clinical Trials

Created by
@SwiftTragedy

Podcast Beta

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is a major issue contributing to the lack of success in Alzheimer's disease clinical trials?

  • Difficulty in designing appropriate clinical trials (correct)
  • Too many participants in the trials
  • Overwhelming success of previous clinical trials
  • Lack of funding for clinical trials
  • Which type of therapy focuses on targeting tau in Alzheimer's disease?

  • Microglia activation therapy
  • Solanezumab
  • Gantenerumab (correct)
  • Anti-Aβ antibodies
  • What was the outcome of the clinical trials with Solanezumab and Gantenerumab?

  • Only Solanezumab showed positive results
  • Both drugs showed significant improvement in cognitive decline
  • Neither drug demonstrated significant benefits (correct)
  • Only Gantenerumab showed positive results
  • Why do researchers face challenges in designing clinical trials for Alzheimer's disease therapies?

    <p>Variability in disease progression and diagnosis</p> Signup and view all the answers

    What is a common focus of therapeutic approaches for addressing Alzheimer's disease?

    <p>Targeting neuroinflammation pathways</p> Signup and view all the answers

    What are the key therapeutic targets for Alzheimer's disease pathology?

    <p>Aβ antibodies</p> Signup and view all the answers

    Which drug is a non-competitive antagonist at NMDA, 5HT3, and nicotinic acetylcholine receptors?

    <p>Memantine</p> Signup and view all the answers

    What is the mode of action of Solanezumab in Alzheimer's disease?

    <p>Anti-Aβ antibodies</p> Signup and view all the answers

    Gantenerumab primarily targets which aspect of Alzheimer's disease pathology?

    <p>Aβ plaques</p> Signup and view all the answers

    Which treatment option aims to reduce glutamate excitotoxicity in Alzheimer's disease?

    <p>Memantine</p> Signup and view all the answers

    What is a common feature of Phase II and III trials for Alzheimer's disease treatments?

    <p>Targeting disease pathomechanisms</p> Signup and view all the answers

    What do tau tangles correlate better with, in terms of cognitive dysfunction, compared to plaques?

    <p>Memory impairment</p> Signup and view all the answers

    What is the primary focus of Aβ immunotherapies?

    <p>Neutralizing the target to prevent aggregation</p> Signup and view all the answers

    What is the main purpose of attracting immune cells in Aβ immunotherapies?

    <p>To degrade Aβ through microglia</p> Signup and view all the answers

    In what phase of clinical trials are anti-Aβ antibodies like Solanezumab and Gantenerumab commonly evaluated?

    <p>Phase II and III trials</p> Signup and view all the answers

    Which of the following is NOT a proposed mechanism of action for Aβ immunotherapies?

    <p>Reducing tau tangles formation</p> Signup and view all the answers

    What is the key difference between an active and passive immunization approach to Aβ immunotherapies?

    <p>Passive immunization stimulates antibody production, while active directly treats with antibodies.</p> Signup and view all the answers

    Use Quizgecko on...
    Browser
    Browser